Terʙinafin (When ATH D01BA02)
When ATH:
D01BA02
Characteristic.
Antifungal agent for oral and topical use. Terbinafine hydrochloride - synthetic derivative of allylamine, white or almost white, fine-grained powder, readily soluble in methanol and methylene chloride, soluble in ethanol, slightly soluble in water. Molecular weight 327,90.
Pharmacological action.
Antifungal, fungicidnoe.
Application.
Fungal skin lesions, hair and nails, candidiasis of the skin and mucous membranes.
Contraindications.
Hypersensitivity, severe hepatocellular and renal failure, blood disease, tumor, metabolic diseases, vascular pathology limbs, pregnancy, lactation, childhood (to 2 years).
Side effects.
Heaviness and pain in the epigastric region, taste disturbance, decreased appetite, nausea, diarrhea, cholestasis, neutropenia, thrombocytopenia, allergic skin reactions; burning sensation, redness and itching in the area of application of the cream.
Cooperation.
Histamine H2-blockers increase plasma concentration (inhibit the biotransformation). Terfenadine reduced, and rifampicin in 2 fold increases clearance.
Dosing and Administration.
Inside, after meal, 1 once a day in the evening in the dose of 250 mg or 2 times a day 125 mg. Locally, cream is applied morning and / or evening to the affected skin, pre-dried and cleaned, as well as the surrounding areas. The average duration in lesions of the skin - 1-2 weeks, nail plate - 3-6 months. Children dose is adjusted to the body weight.
Precautions.
With multi-colored shingles effectively only topical application, systemic administration for onychomycosis is justified in the case of total destruction of most of the nail, the presence of pronounced subungual hyperkeratosis, ineffectiveness of previous local therapy. During treatment (through 2 weeks and at the end) We need to produce the antifungal treatment of footwear, socks and stockings. Severe renal impairment or hepatic determine dose reduction. Avoid getting the cream on the mucous membrane of the eye, nose, mouth.
Cautions.
Removal of the nail plate in the treatment of onychomycosis of hands and feet for 6 Weeks not required.
Cooperation
Active substance | Description of interaction |
Amitriptyline | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Atenolol | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Betaksolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |
Bisoprolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the plasma level. |
Imipramine | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Clomipramine | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Caffeine | FKV. Against the backdrop of slowing terbinafine biotransformation, reduces clearance. |
Maprotilin | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Metoprolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |
Nadolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increase plasma levels. |
Paroxetine | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Pindolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |
Propranolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the amount of blood. |
Rifampicin | FKV. It accelerates and enhances the biotransformation (in 2 times) clearance. |
Selegiline | FKV. In the presence of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increase plasma levels. |
Sertraline | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Sotalol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |
Timolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |
Fluvoxamine | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Fluoxetine | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Cyclosporine | FKV. Against the backdrop of a slight increase clearance of terbinafine. |
Citalopram | FKV. Terbinafine inhibits CYP2D6 (shows in vitro), and can be reasonably expected to slow biotransformation. |
Esmolol | FKV. Against the background of terbinafine - inhibit (shows in vitro) CYP2D6 - can be slow biotransformation and increases the concentration in the blood. |